Positive Trial Data on Symplicity RDN System Likely to Support MDT Stock

Medtronic plc (MDT) recently shared long-term data from its SPYRAL HTN-ON MED clinical trial. The trial data showed significantly greater reductions in 24-hour ambulatory systolic blood pressure (ABPM) and officebased systolic blood pressure (OSBP) in subjects who underwent radiofrequency renal denervation with the company's Symplicity Spyral renal denervation (RDN) system compared to sham patients at two years. The findings were presented at the 2024 Transcatheter Cardiovascular Therapeutics Conference. Th ...